Suppr超能文献

炎症性肠病中的组蛋白去乙酰化酶:新见解

Histone deacetylase in inflammatory bowel disease: novel insights.

作者信息

Li Chunxiao, Gu Shaobo, Zhang Yihong, Zhang Zhenruo, Wang Junzhuo, Gao Ting, Zhong Kangpeng, Shan Keshu, Ye Guoliang, Ke Yini, Chen Yi

机构信息

Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.

Department of Orthopedics, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.

出版信息

Therap Adv Gastroenterol. 2025 Feb 16;18:17562848251318833. doi: 10.1177/17562848251318833. eCollection 2025.

Abstract

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is characterized by chronic nonspecific intestinal inflammation. Despite considerable efforts, IBD remains a heavy burden on society and human health, with increasing morbidity. Posttranslational modification, especially histone acetylation, is a key process in controlling DNA transcriptional activity. Histone deacetylases (HDACs) play a vital role in the mechanism of IBD pathogenesis through histone and nonhistone protein deacetylation. Herein, we present a summary of different categories of HDACs as well as HDAC inhibitors (HDACis) and analyze the role of HDAC inhibition in alleviating IBD along with its mechanism, as well as clinical potential of HDACis in IBD treatment.

摘要

炎症性肠病(IBD),包括溃疡性结肠炎和克罗恩病,其特征为慢性非特异性肠道炎症。尽管付出了巨大努力,但IBD仍然给社会和人类健康带来沉重负担,发病率不断上升。翻译后修饰,尤其是组蛋白乙酰化,是控制DNA转录活性的关键过程。组蛋白去乙酰化酶(HDACs)通过组蛋白和非组蛋白蛋白质去乙酰化在IBD发病机制中发挥重要作用。在此,我们概述了不同类别的HDACs以及HDAC抑制剂(HDACis),并分析了HDAC抑制在减轻IBD中的作用及其机制,以及HDACis在IBD治疗中的临床潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1172/11831641/661985c18724/10.1177_17562848251318833-fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验